Cetera Investment Advisers
NAGE

Cetera Investment Advisers’s Niagen Bioscience NAGE Stock Holding History

Cetera Investment Advisers’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,409
Closed -$162K – 4904
2025
Q3 		$162K Buy
+17,409
New +$176K ﹤0.01% 4209

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cetera Investment Advisers's NAGE Position: Q4 2025 in Review

Cetera Investment Advisers sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 17,409 shares — an estimated $162K sold.

Cetera Investment Advisers first reported a position in NAGE in Q3 2025 and held it in 1 quarter. The position peaked at $162K in Q3 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • Cetera Investment Advisers reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • Cetera Investment Advisers sold 17,409 Niagen Bioscience shares in Q4 2025, an estimated $162K.
  • Cetera Investment Advisers first reported a position in Niagen Bioscience in Q3 2025 and held it in 1 quarter.
  • Cetera Investment Advisers's Niagen Bioscience position peaked at $162K in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Cetera Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.